Logo

NRSNW

NeuroSense Therapeutics Ltd.

NRSNW

NeuroSense Therapeutics Ltd. • NASDAQ
$0.42 ▲ 0.02% (+0.00)
Market Cap $10.36 M
52w High $0.42
52w Low $0.30
Dividend Yield 0%
P/E -0.45
Volume 220
Outstanding Shares 24.67M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $2.346M $-2.354M 0% $-0.093 $-2.342M
Q1-2025 $0 $2.346M ▲ $-2.354M ▼ 0% $-0.093 ▼ $-2.342M ▼
Q4-2024 $0 $1.771M ▼ $-1.801M ▲ 0% $-0.083 ▲ $-1.766M ▲
Q3-2024 $0 $2.107M ▼ $-2.148M ▼ 0% $-0.11 ▼ $-2.102M ▲
Q2-2024 $0 $3.03M $-857K 0% $-0.048 $-3.025M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $666K $1.684M $2.203M $-519K
Q1-2025 $666K ▼ $1.684M ▼ $2.203M ▲ $-519K ▼
Q4-2024 $3.378M ▲ $4.575M ▲ $1.992M ▼ $2.583M ▲
Q3-2024 $344K ▼ $984K ▼ $3.802M ▲ $-2.818M ▼
Q2-2024 $1.243M $1.841M $3.544M $-1.703M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-2.354K $-2K $-6.5 $650.5 $0 $-2K
Q1-2025 $-2.354K ▼ $-2K ▼ $-6.5 ▼ $650.5 ▲ $0 $-2K ▼
Q4-2024 $-1.801K ▲ $0 $0 $0 $0 $0
Q3-2024 $-2.148K ▼ $0 $0 $0 $0 $0
Q2-2024 $-857 $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement NeuroSense is still a classic development‑stage biotech: it has essentially no product revenue yet and runs at a steady loss as it funds research and clinical trials. Losses per share have been persistent, which is normal for a company at this stage but means the story is entirely about future potential, not current profitability. The cost base appears fairly lean, but the business is a long way from self‑funding operations.

Balance Sheet

Balance Sheet The balance sheet is very light, with only modest assets and cash and no meaningful debt. That keeps financial leverage low but also highlights limited internal resources to fund long, expensive trials. The company’s equity value is driven more by its pipeline and intellectual property than by tangible assets. Future strength or weakness in the balance sheet will depend heavily on the success of partnerships, equity raises, or milestone payments.

Cash Flow

Cash Flow Cash flows are negative from operations, reflecting ongoing spending on R&D and corporate costs without offsetting revenue. There is essentially no investment in physical assets, which fits a science‑driven, asset‑light model. The key cash‑flow risk is simple: the company must repeatedly access external funding until a drug is approved or partnered on favorable terms.

Competitive Edge

Competitive Edge NeuroSense focuses on hard‑to‑treat neurodegenerative diseases, where unmet medical need is very high and competition is intense but fragmented. Its main asset, PrimeC for ALS, has encouraging mid‑stage data, orphan drug designation on both sides of the Atlantic, and long‑dated patents on its specific combination and formulation—together forming a meaningful protective moat if late‑stage data are positive. However, larger pharma and other biotechs are also pursuing ALS and Alzheimer’s solutions, so NeuroSense’s edge will ultimately rest on whether its clinical outcomes clearly stand out and it can secure strong commercial partners.

Innovation and R&D

Innovation and R&D The company’s central innovation is its multi‑target combination‑therapy approach: pairing existing drugs in novel, extended‑release formulations to hit several disease mechanisms at once. PrimeC is the lead example, aiming to tackle inflammation, iron accumulation, RNA dysregulation, and neuron loss in ALS. The same platform is being extended into Alzheimer’s (CogniC) and Parkinson’s (StabiliC), showing a coherent strategy rather than one‑off experiments. Collaborations using advanced data science and specialized manufacturers suggest an attempt to ‘punch above its weight’ in R&D, but success still hinges on the outcomes of pivotal trials now moving forward.

Summary

Overall, NeuroSense is an early‑stage, high‑risk, high‑uncertainty biotech whose value is almost entirely tied to its pipeline rather than its current financials. The financial picture shows a lean organization burning cash and relying on external capital, which is typical for its stage but still a key vulnerability. On the positive side, it has a clearly defined scientific strategy, promising ALS data, regulatory designations, and patent protection that could support long‑term exclusivity if its drugs are approved. The next few years—especially the pivotal ALS trial, progress in Alzheimer’s, and any major partnership deals—will likely determine whether today’s scientific promise translates into a sustainable business.